Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic laxative: PEG-3350 retains water in stool via osmotic effect; electrolytes (potassium, sodium, bicarbonate) prevent electrolyte depletion and maintain fluid balance.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Bowel cleansing prior to colonoscopy,Treatment of occasional constipation (OTC use)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Adult dose for colonoscopy preparation: 240 m L (1 glass) orally every 10 minutes until 4 L consumed or rectal effluent is clear. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water orally once daily, not to exceed 7 days.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
The terminal elimination half-life of PEG-3350 is approximately 1.5 hours for the absorbed fraction; the majority is not absorbed and has negligible systemic half-life. Electrolytes have variable half-lives: potassium ~12 hours (renal function dependent), sodium ~6 hours, chloride ~8 hours, bicarbonate ~15 minutes.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
PEG-3350 is not significantly metabolized; excreted unchanged in feces. Electrolytes are absorbed and regulated by renal function.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
PEG-3350 is eliminated essentially unchanged in feces; less than 1% is absorbed and excreted renally. Electrolytes are absorbed and distributed; potassium is primarily excreted renally (90%), sodium and chloride are excreted renally with regulation by aldosterone, and bicarbonate is converted to CO2 and excreted via lungs.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
PEG-3350: negligible binding. Potassium: none. Sodium: none. Chloride: none. Bicarbonate: negligible binding.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
PEG-3350: Vd approximately 0.1 L/kg (confined to extracellular fluid). Potassium: 0.04 L/kg (primarily intracellular, but distribution is tightly regulated). Sodium: 0.4 L/kg (extracellular). Chloride: 0.2 L/kg (extracellular). Bicarbonate: 0.3 L/kg (extracellular).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
PEG-3350: <0.1% absorbed orally; essentially negligible systemic bioavailability. Electrolytes: potassium chloride (100% absorbed), sodium chloride (100% absorbed), sodium bicarbonate (100% absorbed).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No specific dose adjustment for GFR; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to risk of electrolyte disturbances; monitor electrolytes and fluid status.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No adjustment required for Child-Pugh Class A or B; use with caution in Class C due to potential fluid shifts and electrolyte imbalance; monitor closely.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Colonoscopy preparation for pediatric patients: 25 m L/kg/hour orally (maximum 1000 m L/hour) until rectal effluent is clear, up to 4 L total. For constipation: 0.5-1.5 g/kg/day orally divided once daily; max 17 g/day.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Start with lower doses for constipation (e.g., 7.5-10 g/day); ensure adequate hydration; monitor electrolytes and renal function due to age-related decline; use with caution in those with unstable blood pressure or cardiac conditions.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
No FDA boxed warning exists for this combination product, but individual components may have warnings.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Risk of serious fluid and electrolyte disturbances,Use caution in patients with renal impairment, cardiac disease, or electrolyte abnormalities,Avoid in patients with GI obstruction, perforation, or toxic colitis,May cause seizures due to electrolyte shifts (especially hyponatremia)
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis or megacolon,Hypersensitivity to any component,Severe electrolyte abnormalities (e.g., hypernatremia, hypokalemia)
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Avoid solid food during preparation; only clear liquids (e.g., water, clear broth, apple juice) allowed at least 2 hours before procedure. Do not consume red or purple liquids as they may be mistaken for blood. Avoid alcohol.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
PEG-3350, potassium chloride, sodium bicarbonate, and sodium chloride are not absorbed systemically in significant amounts; therefore, no fetal risk is anticipated. No teratogenic effects have been reported. For all trimesters, minimal to no risk.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
These agents are minimally absorbed; thus, excretion into breast milk is negligible. M/P ratio not determined. Considered compatible with breastfeeding.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No dose adjustments required as pharmacokinetics are unchanged; bowel preparation protocols are the same as in non-pregnant patients.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Administer as a split-dose regimen for colonoscopy: first half evening before, second half morning of procedure. Ensure adequate hydration; monitor for electrolyte disturbances in patients with renal impairment or heart failure. Avoid in patients with ileus, gastric retention, or gastrointestinal obstruction. Can cause nausea and bloating; slow rate of ingestion helps. For powdery formulation, reconstitute exactly per instructions to avoid hypernatremia.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Take the medication exactly as prescribed, usually as a split dose for colonoscopy preparation.,Do not add any other ingredients to the solution.,Drink plenty of clear liquids during the preparation to stay hydrated.,You may experience bloating, cramping, or nausea; slow down your drinking if this occurs.,Do not eat solid food during the preparation; only clear liquids are allowed.,Stop drinking the solution at least 2 hours before your procedure.,Contact your doctor if you have severe abdominal pain, vomiting, or if you cannot keep the solution down.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Mycophenolic acid, a prodrug of mycophenolate mofetil, undergoes enterohepatic recirculation and is absorbed in the stomach and proximal small intestine. Sodium bicarbonate, by raising gastric pH, can reduce the dissolution and absorption of mycophenolic acid, leading to decreased systemic exposure and potentially reduced immunosuppressive efficacy. This interaction may increase the risk of transplant rejection when used concurrently."
"Sodium bicarbonate, an alkalizing agent, can increase the gastric pH, which may reduce the dissolution and absorption of topically administered clobetasol propionate if swallowed inadvertently. However, this interaction is not clinically significant for topical application, as systemic absorption of clobetasol is minimal. The theoretical decrease in bioavailability is unlikely to affect efficacy or safety."
"Perphenazine, a phenothiazine antipsychotic, can reduce the absorption of sodium bicarbonate by delaying gastric emptying and increasing gastrointestinal transit time. This results in decreased systemic availability of bicarbonate, potentially attenuating its alkalinizing effect and compromising its efficacy in conditions requiring urinary alkalinization or systemic acidosis correction."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE is a Electrolyte that works by Osmotic laxative: PEG-3350 retains water in stool via osmotic effect; electrolytes (potassium, sodium, bicarbonate) prevent electrolyte depletion and maintain fluid balance.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE is: Adult dose for colonoscopy preparation: 240 m L (1 glass) orally every 10 minutes until 4 L consumed or rectal effluent is clear. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water orally once daily, not to exceed 7 days.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE is classified as Category A/B. PEG-3350, potassium chloride, sodium bicarbonate, and sodium chloride are not absorbed systemically in significant amounts; therefore, no fetal risk is anticipated. No teratogenic . AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.